Recurrent Disseminated Intravascular Coagulation in Metastatic Castration-Resistant Prostate Cancer: A Case Report
Open Access
- 28 September 2022
- journal article
- editorial
- Published by MDPI AG in Diagnostics
- Vol. 12 (10) , 2342
Abstract
Disseminated intravascular coagulation (DIC) is a systemic disease characterized by simultaneous thrombosis, bleeding, and partially excessive fibrinolysis. Systemic shock, trauma, bacterial toxins, and procoagulants-expressing solid and hematologic malignancies are common causes of this life-threatening hemorrhagic complication and often require treatment in intensive care units. We describe a case of an elderly man with recurrent severe bleeding events in the cause of DIC, including epistaxis, hemoptysis, hematuria, and gastrointestinal bleeding. Laboratory investigations revealed elevated prostate-specific antigen (PSA), suggesting an underlying prostate cancer. Despite intensified coagulatory therapy, the coagulation disorder could not be stabilized. A single injection of degarelix, a gonadotropin-releasing hormone (GnRH) receptor antagonist, led to rapid stabilization of the coagulation and decreased PSA within days. One year after initiating androgen-deprivation therapy, there were recurrent transfusion-requiring bleeding events, and a concomitant PSA increase occurred, suggesting metastatic castration-resistant disease associated with DIC. This case emphasizes DIC as a possible primary phenomenon and indicator for the progression of the underlying malignancy, as well as the importance of etiological therapies in the management of DIC.Keywords
Funding Information
- Interdisciplinary Centre for Clinical Research (IZKF) Jena (IZKF-CSPOA19-BG)
This publication has 10 references indexed in Scilit:
- Extracellular Vesicle-Associated Tissue Factor Activity in Prostate Cancer Patients with Disseminated Intravascular CoagulationCancers, 2021
- Apalutamide for Metastatic, Castration-Sensitive Prostate CancerNew England Journal of Medicine, 2019
- Disseminated Intravascular Coagulation in Cancer: An UpdateSeminars in Thrombosis and Hemostasis, 2019
- Disseminated Intravascular Coagulation: An Update on Pathogenesis, Diagnosis, and Therapeutic StrategiesClinical and Applied Thrombosis/Hemostasis, 2018
- Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12‐month, comparative, phase III studyBJU International, 2010
- Procoagulant mechanisms in tumour cellsBest Practice & Research Clinical Haematology, 2009
- The efficacy and safety of degarelix: a 12‐month, comparative, randomized, open‐label, parallel‐group phase III study in patients with prostate cancerBJU International, 2008
- Disseminated Intravascular Coagulation: What's New?Critical Care Clinics, 2005
- Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation.2001
- Towards Definition, Clinical and Laboratory Criteria, and a Scoring System for Disseminated Intravascular CoagulationThrombosis and Haemostasis, 2001